

Marta M Alonso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5994340/publications.pdf>

Version: 2024-02-01

152
papers

5,661
citations

87723

38
h-index

82410

72
g-index

155
all docs

155
docs citations

155
times ranked

10673
citing authors

#	ARTICLE	IF	CITATIONS
1	The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2001.	1.8	4
2	Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas. <i>JCI Insight</i> , 2022, 7, .	2.3	14
3	Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 471-480.	1.9	6
4	Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality. <i>Frontiers in Immunology</i> , 2022, 13, 866892.	2.2	5
5	The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies. <i>Neuro-Oncology</i> , 2022, 24, 1408-1422.	0.6	27
6	Different Effects of Valproic Acid on SLC12A2, SLC12A5 and SLC5A8 Gene Expression in Pediatric Glioblastoma Cells as an Approach to Personalised Therapy. <i>Biomedicines</i> , 2022, 10, 968.	1.4	3
7	DIPG-22. Modifying the tumor microenvironment with a TIM-3 monoclonal antibody as a therapeutic strategy for DIPGs. <i>Neuro-Oncology</i> , 2022, 24, i22-i23.	0.6	1
8	IMMU-18. Targeting Antigen Presenting Cells to improve virotherapy efficacy in Diffuse Midline Gliomas. <i>Neuro-Oncology</i> , 2022, 24, i85-i85.	0.6	0
9	Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. <i>New England Journal of Medicine</i> , 2022, 386, 2471-2481.	13.9	102
10	Local administration of IL-12 with an HC vector results in local and metastatic tumor control in pediatric osteosarcoma. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 23-33.	2.0	2
11	The Effectiveness of Dichloroacetate on Human Glioblastoma Xenograft Growth Depends on Na ⁺ and Mg ²⁺ Cations. <i>Dose-Response</i> , 2021, 19, 155932582199016.	0.7	3
12	Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy. , 2021, 9, e002086.		23
13	IMMU-06. DELTA-24-RGD EXPRESSING POSITIVE IMMUNE MODULATORS SHOW ANTI-DIPG EFFECT AND INCREASE TUMOR IMMUNE INFILTRATION. <i>Neuro-Oncology</i> , 2021, 23, i28-i28.	0.6	0
14	IMMU-01. THE ONCOLYTIC VIRUS DELTA-24-RGD IN COMBINATION WITH AN AGONISTIC CD40 MAB INDUCES A DURABLE AND SYNERGISTIC ANTI-TUMOR IMMUNE EFFECT IN DIPG PRECLINICAL MODELS. <i>Neuro-Oncology</i> , 2021, 23, i26-i27.	0.6	0
15	HGG-15. THE IMIPRIDONE ONC201 IN COMBINATION WITH THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD HAS A SYNERGISTIC EFFECT IN PRECLINICAL MODELS OF PHGGs AND DMGS. <i>Neuro-Oncology</i> , 2021, 23, i20-i20.	0.6	0
16	EPCT-04. RESULTS OF A PHASE 1 STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 WITH RADIOTHERAPY FOR NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). <i>Neuro-Oncology</i> , 2021, 23, i47-i47.	0.6	1
17	IMMU-09. MODULATING THE MYELOID POPULATION IN DIPG MODELS WITH ONCOLYTIC VIRUS AND COMPLEMENT INHIBITORS SHOWS THERAPEUTIC EFFICACY. <i>Neuro-Oncology</i> , 2021, 23, i28-i29.	0.6	0
18	IMMU-08. MICROENVIRONMENT MODULATION BY TIM-3 BLOCKADE IMPROVES THE OUTCOME OF PRECLINICAL DIPG MODELS. <i>Neuro-Oncology</i> , 2021, 23, i28-i28.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Abstract 3053: Armed oncolytic virus for treatment of pediatric diffuse intrinsic pontine glioma. , 2021, , .		0
20	CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models. , 2021, 9, e002644.		25
21	Hitchhiking to brain tumours: stem cell delivery of oncolytic viruses. Lancet Oncology, The, 2021, 22, 1049-1051.	5.1	6
22	Identification of a Dexamethasone Mediated Radioprotection Mechanism Reveals New Therapeutic Vulnerabilities in Glioblastoma. Cancers, 2021, 13, 361.	1.7	8
23	Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET. Clinical Cancer Research, 2021, 27, 1807-1820.	3.2	12
24	Clinical Value of NGS Genomic Studies for Clinical Management of Pediatric and Young Adult Bone Sarcomas. Cancers, 2021, 13, 5436.	1.7	4
25	Sarcoma treatment in the era of molecular medicine. EMBO Molecular Medicine, 2020, 12, e11131.	3.3	154
26	RNU6-1 in circulating exosomes differentiates GBM from non-neoplastic brain lesions and PCNSL but not from brain metastases. Neuro-Oncology Advances, 2020, 2, vdaa010.	0.4	11
27	Immunotherapy with CAR-T cells in paediatric haematology-oncology. Anales De PediatrÃa (English) Tj ETQq1 1 0.784314 rgBT /Overlo	0.1	0
28	Somatic and germline analysis of a familial Rothmundâ€“Thomson syndrome in two siblings with osteosarcoma. Npj Genomic Medicine, 2020, 5, 51.	1.7	3
29	THER-09. ONCOLYTIC ADENOVIRUS, DNX-2401, FOR NAIVE DIFFUSE INTRINSIC PONTINE GLIOMAS: A PHASE I CLINICAL TRIAL. Neuro-Oncology, 2020, 22, iii473-iii473.	0.6	0
30	THER-01. AWAKING THE IMMUNE SYSTEM WITH AN IMMUNO-ONCOLYTIC VIRUS AS A THERAPEUTIC STRATEGY FOR DIPGs. Neuro-Oncology, 2020, 22, iii471-iii471.	0.6	0
31	THER-02. EVALUATION OF THE ONCOLYTIC VIRUS DELTA24-RGD AS AN ANTI-TUMOR AGENT IN PRECLINICAL MODELS OF LOCALIZED AND DISSEMINATED AT/RT. Neuro-Oncology, 2020, 22, iii471-iii471.	0.6	0
32	miR-425-5p, a SOX2 target, regulates the expression of FOXJ3 and RAB31 and promotes the survival of GSCs. Archives of Clinical and Biomedical Research, 2020, 04, 221-238.	0.1	6
33	IMMU-14. ONCOLYTIC ADENOVIRUS DELTA-24-RGD ENGINEERED TO EXPRESS 4-1BBL AS A THERAPEUTIC APPROACH FOR DIPG. Neuro-Oncology, 2020, 22, ii107-ii107.	0.6	0
34	EXTH-39. HEXON SWAPPING MITIGATES ANTI-VIRAL IMMUNE RESPONSE DURING BRAIN TUMOR VIROTHERAPY. Neuro-Oncology, 2020, 22, ii95-ii95.	0.6	0
35	IMMU-39. TIM-3 APTAMER IN COMBINATION WITH RADIOTHERAPY RESULTS IN ENHANCED SURVIVAL IN DIPG MODELS. Neuro-Oncology, 2020, 22, ii113-ii113.	0.6	0
36	CTIM-25. ONCOLYTIC VIRUS FOR DIPG: THE CLINICAL EXPERIENCE WITH DNX-2401. Neuro-Oncology, 2020, 22, ii38-ii38.	0.6	0

#	ARTICLE	IF	CITATIONS
37	IMMU-21. THE COMBINATION OF DELTA-24-ACT WITH AN IMMUNE CHECKPOINT INHIBITOR RESULTS IN ANTI-GLIOMA EFFECT AND IMMUNE MEMORY. <i>Neuro-Oncology</i> , 2020, 22, ii109-ii109.	0.6	0
38	EXTH-60. CHARACTERIZATION OF THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD AS THERAPEUTIC AGENT FOR THE TREATMENT OF THE PEDIATRIC EMBRYONAL BRAIN TUMORS AT/RT AND CNS-PNET. <i>Neuro-Oncology</i> , 2020, 22, ii100-ii100.	0.6	0
39	The Importance of Gender-Related Anticancer Research on Mitochondrial Regulator Sodium Dichloroacetate in Preclinical Studies In Vivo. <i>Cancers</i> , 2019, 11, 1210.	1.7	9
40	The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models. <i>Scientific Reports</i> , 2019, 9, 14368.	1.6	10
41	THER-25. IMMUNE ONCOLYTIC ADENOVIRUS FOR DIPG TREATMENT. <i>Neuro-Oncology</i> , 2019, 21, ii119-ii119.	0.6	0
42	OS5.1 Phase I clinical trial with oncolytic virus DNX-2401 for DIPGs. <i>Neuro-Oncology</i> , 2019, 21, iii11-iii11.	0.6	1
43	P06.01 Delta24-ACT oncolytic adenovirus as a therapeutic approach for DIPG. <i>Neuro-Oncology</i> , 2019, 21, iii36-iii36.	0.6	0
44	Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas. <i>Clinical Cancer Research</i> , 2019, 25, 6801-6814.	3.2	27
45	GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz009.	0.4	21
46	The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. <i>Nature Communications</i> , 2019, 10, 2235.	5.8	96
47	DIPG-04. TRANSLATION OF DNX-2401 FROM THE BENCH TO THE CLINIC FOR PEDIATRIC HIGH GRADE GLIOMAS INCLUDING DIFFUSE INTRINSIC PONTINE GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, ii68-ii69.	0.6	0
48	ATRT-03. EFFICACY OF THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD AS A THERAPEUTIC AGENT FOR THE TREATMENT OF PEDIATRIC EMBRYONAL BRAIN TUMORS. <i>Neuro-Oncology</i> , 2019, 21, ii63-ii63.	0.6	0
49	Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models. <i>Acta Neuropathologica Communications</i> , 2019, 7, 64.	2.4	31
50	PDTM-23. DELTA-24-RGD ONCOLYTIC ADENOVIRUS MEDIATES ANTI-TUMOR EFFECT IN LOCALIZED AND DISSEMINATED AT/RT MURINE MODELS. <i>Neuro-Oncology</i> , 2019, 21, vi192-vi192.	0.6	0
51	EXTH-27. ACTIVATING THE IMMUNITY WITHIN THE TUMOR USING VIROIMMUNOTHERAPY: DELTA-24-RGD ONCOLYTIC ADENOVIRUS ARMED WITH THE IMMUNOPOSITIVE REGULATOR GITRL. <i>Neuro-Oncology</i> , 2019, 21, vi87-vi87.	0.6	0
52	EXTH-11. TREATMENT WITH DELTA-24-RGDOX OF SUBCUTANEOUS TUMORS RESULTS IN ABSOPAL EFFECT ERADICATING INTRACRANIAL MELANOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi84-vi84.	0.6	0
53	IMMU-14. ONCOLYTIC VIRUS EXPRESSING A POSITIVE IMMUNE CHECKPOINT MODULATOR AS A THERAPEUTIC APPROACH FOR DIPG. <i>Neuro-Oncology</i> , 2019, 21, vi122-vi122.	0.6	0
54	PDCT-18 (LTBK-03). PHASE I CLINICAL TRIAL WITH ONCOLYTIC VIRUS DNX-2401 FOR DIPGS. <i>Neuro-Oncology</i> , 2019, 21, vi283-vi284.	0.6	0

#	ARTICLE	IF	CITATIONS
55	P11.23 Oncolytic adenovirus Delta-24-RGD exerts a potent anti-tumor effect in preclinical models of atypical teratoid/rhabdoid tumors. <i>Neuro-Oncology</i> , 2019, 21, iii47-iii47.	0.6	0
56	Oncolytic adenovirus Delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy. <i>Journal of Proteomics</i> , 2019, 194, 168-178.	1.2	8
57	Destress and do not suppress: targeting adrenergic signaling in tumor immunosuppression. <i>Journal of Clinical Investigation</i> , 2019, 129, 5086-5088.	3.9	10
58	Abstract 3117: Delta-24-RGD/DNX-2401: Oncolytic virotherapy for pediatric high grade glioma and DIPG. , 2019, , .		0
59	Abstract 3115: High-capacity adenoviral vectors with controlled expression of interleukin 12 as a new strategy against pediatric osteosarcoma. , 2019, , .		0
60	Linking inflammation and cancer: the unexpected SYK world. <i>Neuro-Oncology</i> , 2018, 20, 582-583.	0.6	13
61	The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 930-941.	0.6	29
62	Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients. <i>Neurosurgery</i> , 2018, 83, 1050-1056.	0.6	40
63	Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors. <i>OncolImmunology</i> , 2018, 7, e1450711.	2.1	3
64	SEOM clinical guidelines for anaplastic gliomas (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 16-21.	1.2	12
65	Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1419-1427.	0.8	477
66	CBMT-19. RNU6-1 ANALYSED IN EXOSOMES FROM SERA AS A NOVEL DIFFERENTIAL BIOMARKER FOR GBM VS NON-NEOPLASTIC BRAIN LESIONS AND NSCPL. <i>Neuro-Oncology</i> , 2018, 20, vi36-vi36.	0.6	0
67	Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models by [18F]FDG and sodium [18F]fluoride PET. <i>BMC Cancer</i> , 2018, 18, 1193.	1.1	11
68	Basic and Translational Advances in Glioblastoma. <i>BioMed Research International</i> , 2018, 2018, 1-2.	0.9	7
69	DNX-2401, an Oncolytic Virus, for the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Gliomas: A Case Report. <i>Frontiers in Oncology</i> , 2018, 8, 61.	1.3	42
70	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.	3.9	86
71	Oncolytic Viruses as Therapeutic Tools for Pediatric Brain Tumors. <i>Cancers</i> , 2018, 10, 226.	1.7	23
72	Oncolytic Virotherapy for Gliomas. , 2018, , 357-384.		4

#	ARTICLE	IF	CITATIONS
73	Spatial and temporal proteome dynamics of glioma cells during oncolytic adenovirus Delta-24-RGD infection. <i>Oncotarget</i> , 2018, 9, 31045-31065.	0.8	8
74	Abstract 3192: Aptamers, antibodies and radiotherapy for the treatment of DIPG. , 2018, , .		0
75	Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope. <i>Journal of Bone Oncology</i> , 2017, 9, 41-47.	1.0	21
76	A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. <i>Journal of Translational Medicine</i> , 2017, 15, 104.	1.8	100
77	A new species of <i>Chionoloma</i> (Pottiaceae) from Central and South America with a key to Neotropical species of the genus. <i>Bryologist</i> , 2017, 120, 340-346.	0.1	8
78	IMMU-03. COMBINATION OF RADIOTHERAPY WITH A4-1BB AGONIST ANTIBODY AND A3 APTAMER RESULTS IN ENHANCED SURVIVAL IN DIPG MODEL. <i>Neuro-Oncology</i> , 2017, 19, iv28-iv28.	0.6	0
79	GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. <i>Cell Reports</i> , 2017, 21, 2183-2197.	2.9	56
80	CBIO-06. POTENTIAL ROLE OF RNU6 ISOLATED FROM CIRCULATING EXOSOMES AS A DIAGNOSTIC BIOMARKER FOR GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2017, 19, vi33-vi34.	0.6	0
81	PDTM-12. THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD MEDIATES AN EFFICIENT ANTITUMOR RESPONSE IN VIVO IN SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMORS. <i>Neuro-Oncology</i> , 2017, 19, vi192-vi192.	0.6	0
82	IMMU-39. COMBINATION OF RADIOTHERAPY WITH A4-1BB AGONIST ANTIBODY AND A3 APTAMER RESULTS IN ENHANCED SURVIVAL IN DIPG MODEL. <i>Neuro-Oncology</i> , 2017, 19, vi121-vi121.	0.6	0
83	DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients. <i>Oncotarget</i> , 2017, 8, 1416-1428.	0.8	193
84	ATIM-08. IMMUNOMARKERS IN THE DNX-2401 (DELTA-24-RGD) ONCOLYTIC VIRUS PHASE I CLINICAL TRIAL. <i>Neuro-Oncology</i> , 2017, 19, vi27-vi27.	0.6	3
85	MEDU-21. TREATMENT OF PNETS WITH THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD RESULTS IN ANTITUMOR EFFECT. <i>Neuro-Oncology</i> , 2017, 19, iv42-iv42.	0.6	0
86	Abstract CT027: Oncolytic virus DNX-2401 with a short course of temozolomide for glioblastoma at first recurrence: Clinical data and prognostic biomarkers. <i>Cancer Research</i> , 2017, 77, CT027-CT027.	0.4	17
87	Development of a DIPG Orthotopic Model in Mice Using an Implantable Guide-Screw System. <i>PLoS ONE</i> , 2017, 12, e0170501.	1.1	11
88	Abstract LB-235: Delta-24-RGD oncolytic adenovirus treatment downmodulates the key regulator of T-cell exhaustion TIM3 in malignant gliomas. , 2017, , .		0
89	Abstract 704: Therapeutic potential of Delta24-ACT, a novel immunostimulatory oncolytic adenovirus, for the treatment of pediatric solid tumors: Initial study in pHGG, DIPG and osteosarcoma. , 2017, , .		0
90	ACTR-15. A PHASE I STUDY OF THE ONCOLYTIC VIRUS DNX-2401 AND A SHORT COURSE TEMOZOLOMIDE FOR GLIOBLASTOMA AT FIRST RECURRENCE. <i>Neuro-Oncology</i> , 2016, 18, vi4-vi4.	0.6	3

#	ARTICLE	IF	CITATIONS
91	HG-51DELTA-24-RDG IN COMBINATION WITH RADIOTHERAPY FOR DIPG: OPENING NEW THERAPEUTIC AVENUES. <i>Neuro-Oncology</i> , 2016, 18, iii58.4-iii59.	0.6	1
92	Conditionally Replicative Adenovirusesâ€”Clinical Trials. , 2016, , 335-348.		1
93	Critical Role of Autophagy in the Processing of Adenovirus Capsid-Incorporated Cancer-Specific Antigens. <i>PLoS ONE</i> , 2016, 11, e0153814.	1.1	19
94	EXTH-09. LOOKING FOR AÂCURE: DELTA-24-RDG AND RADIOTHERAPY FOR DIPG TREATMENT. <i>Neuro-Oncology</i> , 2016, 18, vi61-vi61.	0.6	1
95	PCM-14DEVELOPMENT OF A NEW DIPG ORTHOTOPIC MODEL IN MICE USING AN IMPLANTABLE GUIDED-SCREW SYSTEM. <i>Neuro-Oncology</i> , 2016, 18, iii142.1-iii142.	0.6	0
96	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	0.8	160
97	The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma. <i>Clinical Cancer Research</i> , 2016, 22, 2217-2225.	3.2	38
98	Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression. <i>Oncogene</i> , 2016, 35, 4719-4729.	2.6	27
99	Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPC, and Rad51. <i>Neuro-Oncology</i> , 2016, 18, 1109-1119.	0.6	42
100	Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01. <i>PLoS ONE</i> , 2016, 11, e0147211.	1.1	31
101	Analysis of SOX2-Regulated Transcriptome in Glioma Stem Cells. <i>PLoS ONE</i> , 2016, 11, e0163155.	1.1	12
102	Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas. <i>Oncotarget</i> , 2016, 7, 16146-16157.	0.8	29
103	Salinomycin induced ROS results in abortive autophagy and leads to regulated necrosis in glioblastoma. <i>Oncotarget</i> , 2016, 7, 30626-30641.	0.8	55
104	C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy. <i>Oncogene</i> , 2015, 34, 5295-5301.	2.6	43
105	The nuclear receptor NR2E1/TLX controls senescence. <i>Oncogene</i> , 2015, 34, 4069-4077.	2.6	28
106	Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. <i>Nature Medicine</i> , 2015, 21, 555-559.	15.2	473
107	The Oncolytic Adenovirus Î”24-RGD in Combination With Cisplatin Exerts a Potent Anti-Osteosarcoma Activity. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2287-2296.	3.1	26
108	A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. <i>Neuro-Oncology</i> , 2014, 16, 520-527.	0.6	298

#	ARTICLE	IF	CITATIONS
109	ME-05 * COUNTERATTACKING THE FORCE BEHIND GLIOMA INVASION. <i>Neuro-Oncology</i> , 2014, 16, v120-v120.	0.6	0
110	Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. <i>Oncotarget</i> , 2014, 5, 2208-2220.	0.8	108
111	Role of SOX family of transcription factors in central nervous system tumors. <i>American Journal of Cancer Research</i> , 2014, 4, 312-24.	1.4	42
112	Involvement of miRNAs in the Differentiation of Human Glioblastoma Multiforme Stem-Like Cells. <i>PLoS ONE</i> , 2013, 8, e77098.	1.1	64
113	Targeting Brain Tumor Stem Cells with Oncolytic Adenoviruses. <i>Methods in Molecular Biology</i> , 2012, 797, 111-125.	0.4	22
114	PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. <i>Leukemia</i> , 2011, 25, 606-614.	3.3	124
115	MicroRNA-451 Is Involved in the Self-renewal, Tumorigenicity, and Chemoresistance of Colorectal Cancer Stem Cells. <i>Stem Cells</i> , 2011, 29, 1661-1671.	1.4	248
116	Malignant Gliomas: Role of E2F1 Transcription Factor. , 2011, , 89-97.		2
117	Genetic and Epigenetic Modifications of Sox2 Contribute to the Invasive Phenotype of Malignant Gliomas. <i>PLoS ONE</i> , 2011, 6, e26740.	1.1	187
118	Abstract 5402: Enhancing autophagy as a novel approach to target osteosarcoma: combination of Oncolytic adenovirus and chemotherapy. , 2011, , .		1
119	Abstract 3307: The multitasking of Sox2: Maintaining the stemness and inducing the malignant phenotype of gliomas. , 2011, , .		0
120	EV11 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2. <i>British Journal of Cancer</i> , 2010, 103, 1292-1296.	2.9	33
121	The RB-E2F1 Pathway Regulates Autophagy. <i>Cancer Research</i> , 2010, 70, 7882-7893.	0.4	107
122	RB-E2F1. <i>Autophagy</i> , 2010, 6, 1216-1217.	4.3	13
123	Tie2/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype. <i>Oncotarget</i> , 2010, 1, 700-9.	0.8	37
124	Tie2/TEK Modulates the Interaction of Glioma and Brain Tumor Stem Cells with Endothelial Cells and Promotes an Invasive Phenotype. <i>Oncotarget</i> , 2010, 1, 700-709.	0.8	56
125	Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. <i>Cancer Gene Therapy</i> , 2009, 16, 256-265.	2.2	42
126	Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters. <i>Oncogene</i> , 2009, 28, 2358-2363.	2.6	48

#	ARTICLE	IF	CITATIONS
127	Estradiol induces type 8 17 β -hydroxysteroid dehydrogenase expression: crosstalk between estrogen receptor α and C/EBP β . <i>Journal of Endocrinology</i> , 2009, 200, 85-92.	1.2	20
128	Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating HIF-1 α levels in gliomas. <i>Oncogene</i> , 2008, 27, 1310-1314.	2.6	17
129	E2F1 in gliomas: A paradigm of oncogene addiction. <i>Cancer Letters</i> , 2008, 263, 157-163.	3.2	42
130	Delta-24-RGD in Combination With RAD001 Induces Enhanced Anti-glioma Effect via Autophagic Cell Death. <i>Molecular Therapy</i> , 2008, 16, 487-493.	3.7	105
131	Interspecies adenovirus fiber shows "evolutionary" advantage for oncolytic therapy of gliomas. <i>Cancer Biology and Therapy</i> , 2008, 7, 794-796.	1.5	0
132	Examination of the Therapeutic Potential of Delta-24-RGD in Brain Tumor Stem Cells: Role of Autophagic Cell Death. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1410-1414.	3.0	268
133	Cell Cycle-Dependent Nuclear Export of Phosphatase and Tensin Homologue Tumor Suppressor Is Regulated by the Phosphoinositide-3-Kinase Signaling Cascade. <i>Cancer Research</i> , 2007, 67, 11054-11063.	0.4	45
134	Transgenic E2F1 Expression in the Mouse Brain Induces a Human-Like Bimodal Pattern of Tumors. <i>Cancer Research</i> , 2007, 67, 4005-4009.	0.4	29
135	ICOVIR-5 Shows E2F1 Addiction and Potent Antiglioma Effect <i>in vivo</i> . <i>Cancer Research</i> , 2007, 67, 8255-8263.	0.4	63
136	Adenovirus-Based Strategies Overcome Temozolomide Resistance by Silencing the O6-Methylguanine-DNA Methyltransferase Promoter. <i>Cancer Research</i> , 2007, 67, 11499-11504.	0.4	130
137	Transcriptional regulation of the human type 8 17 β -hydroxysteroid dehydrogenase gene by C/EBP β . <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007, 105, 131-139.	1.2	19
138	Systemic Toxicity-Efficacy Profile of ICOVIR-5, a Potent and Selective Oncolytic Adenovirus Based on the pRB Pathway. <i>Molecular Therapy</i> , 2007, 15, 1607-1615.	3.7	84
139	Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect <i>in vivo</i> . <i>Cancer Gene Therapy</i> , 2007, 14, 756-761.	2.2	61
140	Sustained Angiopoietin-2 Expression Disrupts Vessel Formation and Inhibits Glioma Growth. <i>Neoplasia</i> , 2006, 8, 419-428.	2.3	38
141	E2F1 and Telomerase: Alliance in the Dark Side. <i>Cell Cycle</i> , 2006, 5, 930-935.	1.3	22
142	Expression of the Receptor Tyrosine Kinase Tie2 in Neoplastic Glial Cells Is Associated with Integrin β 1-Dependent Adhesion to the Extracellular Matrix. <i>Molecular Cancer Research</i> , 2006, 4, 915-926.	1.5	67
143	Delta-24 Increases the Expression and Activity of Topoisomerase I and Enhances the Antiglioma Effect of Irinotecan. <i>Clinical Cancer Research</i> , 2006, 12, 556-562.	3.2	51
144	A novel CRM1-dependent nuclear export signal in adenoviral E1A protein regulated by phosphorylation. <i>FASEB Journal</i> , 2006, 20, 2603-2605.	0.2	10

#	ARTICLE	IF	CITATIONS
145	320. Modeling Human Brain Cancer in Transgenic E2F1 Mice. <i>Molecular Therapy</i> , 2006, 13, S122.	3.7	0
146	Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1585-1592.	1.1	26
147	Expression of Transcription Factor E2F1 and Telomerase in Glioblastomas: Mechanistic Linkage and Prognostic Significance. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1589-1600.	3.0	57
148	Downmodulation of E1 A Protein Expression as a Novel Strategy to Design Cancer-Selective Adenoviruses. <i>Neoplasia</i> , 2005, 7, 723-729.	2.3	13
149	Comparative Effect of Oncolytic Adenoviruses with E1 A or E113-55 kDa Deletions in Malignant Gliomas. <i>Neoplasia</i> , 2005, 7, 48-56.	2.3	35
150	A novel E1A/E1B mutant adenovirus induces glioma regression in vivo. <i>Oncogene</i> , 2004, 23, 1821-1828.	2.6	60
151	New benzo(b)thiophenesulphonamide 1,1-dioxide derivatives induce a reactive oxygen species-mediated process of apoptosis in tumour cells. <i>Oncogene</i> , 2003, 22, 3759-3769.	2.6	26
152	New cytotoxic benzo(b)thiophenilsulfonamide 1,1-dioxide derivatives inhibit a NADH oxidase located in plasma membranes of tumour cells. <i>British Journal of Cancer</i> , 2001, 85, 1400-1402.	2.9	10